

Our Corporate Responsibility 2016/2017 – GRI Index

Preparation of CSL Limited's Our Corporate Responsibility 2016/2017 Report followed the Global Reporting Initiative's (GRI) G4 Sustainability Reporting Guidelines. We have self-assessed our report as in accordance core to GRI G4's Guidelines.

General Standard Disclosures		
Indicator	Description	CSL's Response (pages referenced can be found in Our Corporate Responsibility 2016/2017)
Strategy and Analysis		
G4-1	Statement from the CEO	Page 4
Organisational Profile		
G4-3	Name of organisation	Page 6 to 8
G4-4	Primary brands, products, and services	Visit www.csl.com.au
G4-5	Location of headquarters	Page 7
G4-6	Countries of operation	Page 7
G4-7	Nature of ownership and legal form	Page 7 and CSL's 2016-2017 Annual Report page 85, on our website www.csl.com.au
G4-8	Markets served	Page 6 to 8
G4-9	Scale of the organisation	Page 7
G4-10	Workforce overview	Page 18 Influenza vaccine and plasma-derived therapy manufacture is driven by fluctuating demands and the Seqirus and CSL Plasma business units, respectively, may adjust its workforce to meet such demands.
G4-11	Coverage of collective bargaining agreements	Page 18
G4-12	Supply chain	Page 9 and 31
G4-13	Changes during the reporting period	Page 2
G4-14	Precautionary approach or principle	Refer to CSL's Risk Framework in our 2016-2017 Annual Report page 47 on our website www.csl.com.au
G4-15	External sustainability initiatives subscribed to	As listed throughout the document and on our website www.csl.com.au
G4-16	Association and advocacy organisations	As listed throughout the document.
Identified Material Aspects and Boundaries		
G4-17	List of entities in the financial statements	Page 8 and CSL's 2016-2017 Annual Report page 85, on our website www.csl.com.au
G4-18	Process for defining report content and boundaries	Page 10 and 14
G4-19	Material aspects/issues	Page 14
G4-20	Aspect boundaries for material aspects/issues within CSL	Page 14
G4-21	Aspect boundaries for material aspects/issues outside CSL	Page 14
G4-22	Impacts of restatements	Page 2 and as footnoted with appropriate data sets
G4-23	Significant changes in scope and aspect boundaries	Page 2 and as footnoted with appropriate data sets
Stakeholder Engagement		
G4-24	Stakeholder groups engaged	Page 11 and our website http://corporateresponsibility.csl.com.au/
G4-25	Identification and selection of stakeholders	Page 11 and our website http://corporateresponsibility.csl.com.au/
G4-26	Approach to stakeholder engagement	Page 11 and our website http://corporateresponsibility.csl.com.au/
G4-27	Key topics and concerns raised by stakeholders	Page 11 and our website http://corporateresponsibility.csl.com.au/
Report Profile		
G4-28	Reporting period	Page 2
G4-29	Date of most recent report	Page 2
G4-30	Reporting cycle	Page 2

G4-31	Contact point for the report	Page 2
G4-32	GRI Content Index for 'in accordance – core' option	Available on our website http://corporateresponsibility.csl.com.au/
G4-33	External assurance	Page 2 and 50
Governance		
G4-34	Governance and structure of the organisation	Refer to CSL's Corporate Governance Statement, available on our website http://annualreport.csl.com.au/our-company/corporate-governance.htm
Ethics and Integrity		
G4-56	Description of the organisation's values and principles	Page 9 and 11

Specific Standard Disclosures		
Material Aspect	DMA and Indicator * Indicates a CSL developed indicator that is not covered by GRI G4.	CSL's Response
Product Safety and Quality	DMA	Page 28 and our website http://corporateresponsibility.csl.com.au/
	PR2	Page 28
Conduct of Clinical Trials	DMA	Page 22 and our website http://corporateresponsibility.csl.com.au/
	Number of regulatory agency inspections*	Page 22
Ethical Marketing	DMA	Page 39 and our website http://corporateresponsibility.csl.com.au/
	PR7	Page 49
Plasma Donations	DMA	Page 30 and our website http://corporateresponsibility.csl.com.au/
	Percentage of surveyed plasma donors willing to donate again*	Page 30
Bribery and Corruption	DMA	Page 37 and our website http://corporateresponsibility.csl.com.au/
	SO3	Page 37
Innovation Process and Management	DMA	Page 19 and our website http://corporateresponsibility.csl.com.au/
	Investment spend, number of clinical trials in operation, number product registrations or new indications*	Page 19 to 26
Anti-Competitive Behaviour	DMA	Page 34 and our website http://corporateresponsibility.csl.com.au/
	SO7	Page 34
Sole Supplier of Critical Medical Products	DMA	Page 31 and our website http://corporateresponsibility.csl.com.au/
	Status of CSL's watch-list of products.	On our website http://corporateresponsibility.csl.com.au/
Human Rights	DMA	Page 17 and on our website http://corporateresponsibility.csl.com.au/
	Steps taken to prevent and mitigate modern slavery in our direct operations and in the supply chain*	On our website http://corporateresponsibility.csl.com.au/
Data Protection and Privacy	DMA	Page 39
	PR8	Data for this indicator is not available. CSL is exploring possible performance indicators that best reflect our priority areas in respect of the management of this aspect. We seek to disclose performance indicators in future reports.
Access to Medicines	DMA	Page 37 and 43 and on our website http://corporateresponsibility.csl.com.au/
	Support for access programs in developing countries*	Page 37 and 43

Transparency of Interactions with Government	DMA	Page 34
	SO6	CSL does not undertake in-kind contributions and data for indirect contributions is not available. Support for trade associations is typically untied and industry related. Full disclosure of our policy positions and advocacy, where trade associations and/or charities may be involved, is detailed on page 37.
Targeted Community Support	DMA	Page 40 to 49
	Investment across key priority areas*	Page 40
Counterfeit Medicines	DMA	Page 31 and on our website http://corporateresponsibility.csl.com.au/
	Instances of counterfeit medicines*	Page 31